The aim of this prospective, non-interventional post-marketing surveillance study is to obtain data on safety and efficacy of Levitra in routine treatment of erectile dysfunction. Furthermore, the data collection particularly focuses on the experience of the patient and his satisfaction with the treatment. Treatment naive patients as well as pre-treated patients will be included in the study.The maximum observation period per patient is 12 months.Besides the physician's documentation, the patient should fill out a questionnaire at every visit. The questionnaires will be handed out and collected by the physician. Furthermore, an additional questionnaire for the patient's partner can be distributed at each visit in case the partner is willing to participate.
Study Type
OBSERVATIONAL
Enrollment
7,293
Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
Unnamed facility
Many Locations, China
Unnamed facility
Many Locations, Croatia
Unnamed facility
Many Locations, France
Unnamed facility
Many Locations, Germany
Unnamed facility
Many Locations, Hungary
Unnamed facility
Many Locations, Indonesia
Unnamed facility
Many Locations, Malaysia
Unnamed facility
Many Locations, Poland
Unnamed facility
Many Locations, Saudi Arabia
Unnamed facility
Many Locations, Singapore
...and 5 more locations
Physician's assessment of safety (incidence of adverse events)
Time frame: During observation period
Severity of ED symptoms
Time frame: End of study
General quality of partnership as assessed by patient
Time frame: Initial visit and after 3, 6, 9 and 12 months
General quality of partnership as assessed by partner
Time frame: Initial visit and after 3, 6, 9 and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.